These expression patterns mirror our findings of increased brain, breast, colon, and hematological cancers, further strengthening the association between LRRK2 and cancer and increasing the value of targeting LRRK2 for therapeutic treatment of both PD and cancer. This evidence concerns the gene LRRK2 and cancer.